Gain Therapeutics (GANX) Competitors $1.58 -0.03 (-1.55%) Closing price 04:00 PM EasternExtended Trading$1.57 -0.01 (-0.95%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. CTMX, DRUG, SOPH, FDMT, YMAB, ENGN, EPRX, GNFT, OGI, and NLTXShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), SOPHiA GENETICS (SOPH), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Organigram Global (OGI), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Its Competitors CytomX Therapeutics Bright Minds Biosciences SOPHiA GENETICS 4D Molecular Therapeutics Y-mAbs Therapeutics enGene Eupraxia Pharmaceuticals GENFIT Organigram Global Neoleukin Therapeutics Gain Therapeutics (NASDAQ:GANX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Does the media prefer GANX or CTMX? In the previous week, Gain Therapeutics had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Gain Therapeutics and 0 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.31 beat Gain Therapeutics' score of 0.61 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Gain Therapeutics Positive CytomX Therapeutics Positive Which has stronger earnings and valuation, GANX or CTMX? CytomX Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K953.22-$20.41M-$0.86-1.84CytomX Therapeutics$138.10M1.39$31.87M$0.484.96 Do analysts prefer GANX or CTMX? Gain Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 417.35%. CytomX Therapeutics has a consensus price target of $5.33, suggesting a potential upside of 124.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Gain Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GANX or CTMX more profitable? CytomX Therapeutics has a net margin of 28.22% compared to Gain Therapeutics' net margin of 0.00%. Gain Therapeutics' return on equity of -247.55% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -247.55% -146.06% CytomX Therapeutics 28.22%-553.71%32.21% Do insiders & institutionals have more ownership in GANX or CTMX? 12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, GANX or CTMX? Gain Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. SummaryCytomX Therapeutics beats Gain Therapeutics on 9 of the 17 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.41M$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio-1.844.4521.0120.09Price / Sales953.22709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book5.665.008.125.65Net Income-$20.41M$30.99M$3.25B$257.91M7 Day Performance-8.38%1.69%0.97%2.09%1 Month Performance-11.45%9.20%7.36%11.13%1 Year Performance29.92%-1.25%31.31%18.40% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.344 of 5 stars$1.59-1.6%$8.20+417.4%+26.8%$48.41M$50K-1.8420CTMXCytomX Therapeutics4.1776 of 5 stars$2.37-5.2%$5.33+125.0%+65.3%$201.55M$138.10M4.94170Positive NewsDRUGBright Minds Biosciences2.4488 of 5 stars$27.33-3.7%$83.25+204.6%+2,102.5%$199.84MN/A-75.91N/APositive NewsSOPHSOPHiA GENETICS2.7866 of 5 stars$3.25+8.7%$7.00+115.4%-20.4%$199.39M$65.17M-3.25520High Trading VolumeFDMT4D Molecular Therapeutics2.2164 of 5 stars$3.95-6.8%$29.56+648.2%-76.0%$196.42M$40K-1.24120YMABY-mAbs Therapeutics4.1825 of 5 stars$4.22-1.9%$15.60+269.7%-65.7%$194.72M$87.68M-6.59150Positive NewsENGNenGene2.876 of 5 stars$3.81+0.3%$23.29+511.2%-59.4%$194.20MN/A-2.3131EPRXEupraxia Pharmaceuticals2.288 of 5 stars$5.54+2.8%$11.00+98.6%+108.1%$193.81MN/A-7.2929GNFTGENFIT2.4738 of 5 stars$3.69-4.8%$13.00+252.7%-17.0%$193.49M$76.77M0.00120Positive NewsUpcoming EarningsGap UpOGIOrganigram Global0.8702 of 5 stars$1.39-2.8%N/A-13.6%$191.53M$117.47M13.90860NLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-49.2%$188.81MN/A-6.4690 Related Companies and Tools Related Companies CytomX Therapeutics Alternatives Bright Minds Biosciences Alternatives SOPHiA GENETICS Alternatives 4D Molecular Therapeutics Alternatives Y-mAbs Therapeutics Alternatives enGene Alternatives Eupraxia Pharmaceuticals Alternatives GENFIT Alternatives Organigram Global Alternatives Neoleukin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts